---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001328"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:53:00.789900+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139

## Summary
- Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.
- Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.
- Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.
- Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.
- Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026.

## SEC filing metadata
- accession: 0001753926-25-001328
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/0001753926-25-001328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001328/vani-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001328
- JSON: https://secwatch.observer/filing/0001753926-25-001328.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.